Table 3

Yield of referable eye disease for individuals with type 1 or type 2 diabetes by year of screening

 Type 1 diabetesType 2 diabetes
 2006200720082009201020062007200820092010
No eye disease1886 (38.0)5368 (41.3)5872 (43.8)5675 (41.7)5765 (41.6)22 750 (66.2)71 156 (68.4)80 961 (70.4)79 656 (69.8)81 894 (70.7)
Non-referable eye disease2346 (47.2)5943 (45.8)6146 (45.9)6458 (47.5)6577 (47.4)9563 (27.8)27 491 (26.4)29 951 (26.0)30 393 (26.6)29 812 (25.7)
Referable eye disease735 (14.8)1676 (12.9)1377 (10.3)1465 (10.8)1521 (11.0)2038 (5.9)5315 (5.1)4128 (3.6)4087 (3.6)4113 (3.6)
Referable maculopathy alone434 (8.7)1023 (7.9)856 (6.4)945 (7.0)962 (6.9)1229 (3.6)3555 (3.4)2941 (2.6)3034 (2.7)3131 (2.7)
Referable background retinopathy±maculopathy161 (3.2)318 (2.4)237 (1.8)202 (1.5)212 (1.5)554 (1.6)1129 (1.1)740 (0.6)596 (0.5)537 (0.5)
Proliferative retinopathy±maculopathy140 (2.8)335 (2.6)284 (2.1)318 (2.3)347 (2.5)255 (0.7)631 (0.6)447 (0.4)457 (0.4)445 (0.4)
Total (100%)496712 98713 39513 59813 86334 351103 962115 040114 136115 819
  • Referable eye disease comprises referable maculopathy (M2 on the DRS grading scheme), preproliferative retinopathy (R3 on the DRS grading scheme) and proliferative retinopathy (R4 on the DRS grading scheme).

  • DRS, Diabetic Retinopathy Screening service.